Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
623.95 | 12,144 Cr | 49.91 | 4.69 | 0.10 | 9.39 | 10.73 | 6.57 | ||
263.00 | 11,941 Cr | 28.57 | 3.95 | 0.34 | 13.82 | 17.37 | 10.88 | ||
259.85 | 11,352 Cr | 71.05 | 4.03 | 0.00 | 7.07 | 13.01 | 4.44 | ||
6780.50 | 11,257 Cr | 34.43 | 21.46 | 6.12 | 62.32 | 84.14 | 38.86 | ||
576.55 | 10,906 Cr | 44.01 | 5.05 | 0.19 | 18.22 | 24.16 | 15.10 | ||
4671.45 | 10,773 Cr | 41.77 | 28.05 | 1.60 | 62.53 | 75.60 | 47.15 | ||
676.00 | 10,638 Cr | 41.69 | 3.21 | 0.43 | 7.70 | 10.95 | 4.71 | ||
| Median: 7 Co. | — | 623.95 | 11,257 Cr | 41.77 | 4.69 | 0.34 | 13.82 | 17.37 | 10.88 |
Viyash Scientific Ltd (VIYASH) is currently trading at 253.45 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Viyash Scientific Limited, formerly Sequent Scientific Limited, is engaged in the pharmaceutical business with a focus on animal health, formulations, and API. The company has shown solid financial performance in Q3 FY26, with revenues of ₹8,584 million and EBITDA growing by 64% YoY. It has achieved significant margin expansion, reflecting strong operational efficiencies and strategic cost optimization. The merger with Sequent Scientific Limited has enabled Viyash to unlock synergies across various business units, enhancing R&D, manufacturing capabilities, and market reach. This transformative merger has laid a strong foundation for sustained profitability and business growth. Viyash has successfully entered into strategic partnerships, including a noteworthy agreement with Boehringer Ingelheim for distributing companion animal products in India, underscoring its commitment to expanding its footprint in the animal health sector. The company is focusing on expanding its R&D capabilities, emphasizing the development of complex generics, which positions it to capture significant opportunities in the growing generics market for companion animals.
Over the past 52 weeks, Viyash Scientific Ltd has traded between a low of ₹166.20 and a high of ₹297.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Viyash Scientific Ltd has a market capitalization of approximately 11,352.21. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Viyash Scientific Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 71.05 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 11,352.21 Cr, Viyash Scientific Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Viyash Scientific Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Viyash Scientific Ltd is 71.05. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Viyash Scientific, through its wholly owned subsidiary Alivira Animal Health, is acquiring 100% of BioForLife Italia S.r.l., a pet care company based in Milan.
Standalone net sales were reported at ₹372.49 crore for March 2026, up from ₹42.33 crore in March 2025.
The stock reacted to higher Q4 FY26 revenue, a strong jump in EBITDA, margin expansion to 21.7%, and a swing in PAT to ₹66.38 crore versus a year-ago loss.
Viyash Scientific reported Q4 FY26 consolidated net profit of ₹52.11 crore, compared with a net loss of ₹26.24 crore in Q4 FY25.
Merger/Acquisition
Viyash Scientific's step-down subsidiary Alivira Animal Health (Ireland) executed an SPA on 2026-07-21 to acquire 100% of BioForLife Italia for ~EUR16.976m (EUR15.0m at closing; ~EUR1.976m deferred). Transaction subject to Italian FDI/Golden Power and other conditions.
Merger/Acquisition
Viyash Scientific's step-down subsidiary Alivira Animal Health Ltd (Ireland) executed a SPA to acquire 100% of BioForLife Italia s.r.l. for ~EUR16.976m (EUR15.0m at closing; ~EUR1.976m deferred). Completion subject to Italian FDI/Golden Power clearance.
Viyash Scientific Limited, formerly Sequent Scientific Limited, is engaged in the pharmaceutical business with a focus on animal health, formulations, and API. The company has shown solid financial performance in Q3 FY26, with revenues of ₹8,584 million and EBITDA growing by 64% YoY. It has achieved significant margin expansion, reflecting strong operational efficiencies and strategic cost optimization.
The merger with Sequent Scientific Limited has enabled Viyash to unlock synergies across various business units, enhancing R&D, manufacturing capabilities, and market reach. This transformative merger has laid a strong foundation for sustained profitability and business growth.
Viyash has successfully entered into strategic partnerships, including a noteworthy agreement with Boehringer Ingelheim for distributing companion animal products in India, underscoring its commitment to expanding its footprint in the animal health sector.
The company is focusing on expanding its R&D capabilities, emphasizing the development of complex generics, which positions it to capture significant opportunities in the growing generics market for companion animals.
Pharmaceuticals & Biotechnology
Pharmaceuticals
11,073 Cr
High Risk
69.3
37.2
0.7
4.0
297.90
166.20
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
3
Neutral
3
Bullish
8
Bearish
25
Neutral
3
Bullish
18
Bearish
22
Neutral
0
Bullish
10
